Simplifying Software Security: Veracode Enhances Frictionless Experience for Developers
14.9.2022 21:33:00 EEST | Business Wire | Press release
Black Hat (booth #2428) – Veracode, a leading global provider of application security testing solutions, today announced the enhancement of its Continuous Software Security Platform with substantial improvements to its integrated developer experience. New features include extended integrations to support software composition analysis (SCA), a software bill of materials (SBOM) Application Programming Interface (API), and additional language and framework support for static analysis, further enhancing developers’ ability to secure software in the environments where they work.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220809005141/en/
Fig. 1 Veracode “Beat the Heat” security flaw heat map, State of Software Security Report v12 (Graphic: Business Wire)
Brian Roche, Chief Product Officer at Veracode, said, “Modern applications are mostly assembled, not written from scratch. Open-source code makes up a significant proportion of audited code bases—for example, 97 percent of the typical Java application is made up of open-source libraries*—increasing security risk and the need to identify supply chain risk. Our SBOM API, is designed to make it easier for developers to inventory their code base, including third-party components, allowing them to act quickly if new vulnerabilities emerge. Since the launch of our Continuous Software Security Platform in May, we have introduced additional capabilities that meet developers right where they work: in the integrated developer environment (IDE), code repository, and command line interface. These innovations are designed to drive adoption by making the platform even more developer friendly.”
Facilitating DevSecOps
Veracode’s platform supports 100+ languages and frameworks, including those for cloud-native application development and older languages used with legacy assets, like COBOL. Large enterprises have applications across myriad languages and being able to deploy a continuous security testing solution across them simplifies the process, while providing consistent results. The company’s latest State of Software Security (SoSS) 12 research analyzed the most common flaws by language and revealed that a prevalent flaw for one language may not be of any concern for another. For example, cross-site scripting (XSS) is the most common flaw for PHP, at 77 percent, but doesn’t even make the top 10 for C++*. Moreover, flaws change constantly, meaning that even if a flaw isn’t prevalent in a programming language, practitioners should still take active steps to prevent it from impacting their code. Since remediation tactics vary by flaw and programming language, having a broad array of language support in one place makes developers’ jobs easier by freeing up their time to focus on meeting tight deployment deadlines.
Frequent scanning of first- and third-party code mitigates the risk from both proprietary and open-source vulnerabilities, such as Log4j. Veracode’s new developer-centric tools and services are designed to make this a quicker and easier process, particularly with the additional capability of third-party proprietary library scanning.
Peter Evans, Engineering Director at QAD Precision GTTE, said, “Veracode brought a complete platform for us to build security tools into our development pipelines, as well as helped us grow our knowledge to keep getting better at security. Veracode was also a good fit because the platform can scan Java code in the Spring framework where we develop our software. We’ve gone from reviewing code to integrating continuous scans into our daily pipelines. Security threats don’t stand still and Veracode provides us the tools to keep up with the latest vulnerabilities and rules.”
Notable updates to the Veracode Continuous Software Security platform include:
SBOM for SCA
- With government regulations driving standards for securing software supply chains, having an SBOM is increasingly important for organizations. Veracode’s SBOM API in SCA enables developers to easily generate an SBOM in CycloneDX JSON format—one of the approved formats for compliance with the U.S. Executive Order. This helps confirm the code they’re using, or building, is free from vulnerabilities.
IDE and Integrations for SCA
To make software security a seamless experience, Veracode continues to introduce integrations that meet developers where they work.
- The Veracode Azure DevOps Extension has a new “SCA Flaw Importer” to automatically import SCA flaws into Azure DevOps Boards and Work Items
- The soon-to-be-released Veracode for Visual Studio Code extension provides detailed information on vulnerabilities, licence risks, and recommended versions of open-source libraries and transitive dependencies so developers can rapidly respond to any risks
Expanded Frameworks and Languages Support for Static Analysis
- The company is committed to keeping up with the latest language and frameworks with which developers work, adding support for Rails 7.0, Ruby 3.x, and PHP Symfony
Roche concluded, “As a pioneer of application security, we are uniquely positioned to combine unrivalled experience with the latest innovations in cloud development. Unlike on-premise vendors, our SaaS solution is both scalable and elastic, meaning customers are always prepared to meet unexpected demand. Powered by nearly two decades of cumulative data, our platform provides detailed comparative historical reviews against industry benchmarks and peers—a level of insight highly relevant for leadership teams and the board. Our platform also saves developers time by delivering highly accurate results and enabling them to find and fix vulnerabilities in minutes, meaning they can ship code quickly with the confidence that it is secure.”
Developers can learn more about Veracode’s platform, the frictionless developer experience, and how to simply and maturely secure their SDLC by visiting Veracode’s booth #2428 at Black Hat USA.
*Veracode State of Software Security Report v12, February 2022
About Veracode
Veracode is a leading AppSec partner for creating secure software, reducing the risk of security breach, and increasing security and development teams’ productivity. As a result, companies using Veracode can move their business, and the world, forward. With its combination of process automation, integrations, speed, and responsiveness, Veracode helps companies get accurate and reliable results to focus their efforts on fixing, not just finding, potential vulnerabilities.
Learn more at www.veracode.com, on the Veracode blog and on Twitter.
Copyright © 2022 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220809005141/en/
Contact information
Press and Media
Katy Gwilliam
Head of Global PR, Veracode
kgwilliam@veracode.com
+44.7584.341.110
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom